1. Academic Validation
  2. Sphingosine kinase-2 inhibition improves mitochondrial function and survival after hepatic ischemia-reperfusion

Sphingosine kinase-2 inhibition improves mitochondrial function and survival after hepatic ischemia-reperfusion

  • J Hepatol. 2012 Jan;56(1):137-45. doi: 10.1016/j.jhep.2011.05.025.
Yanjun Shi 1 Hasibur Rehman Venkat K Ramshesh Justin Schwartz Qinlong Liu Yasodha Krishnasamy Xun Zhang John J Lemasters Charles D Smith Zhi Zhong
Affiliations

Affiliation

  • 1 Department of Pharmaceutical and Biomedical Sciences, Medical University of South Carolina, Charleston, SC 29425, USA.
Abstract

Background & aims: The mitochondrial permeability transition (MPT) and inflammation play important roles in liver injury caused by ischemia-reperfusion (IR). This study investigated the roles of sphingosine kinase-2 (SK2) in mitochondrial dysfunction and inflammation after hepatic IR.

Methods: Mice were gavaged with vehicle or ABC294640 (50 mg/kg), a selective inhibitor of SK2, 1 h before surgery and subjected to 1 h-warm ischemia to ~70% of the liver followed by reperfusion.

Results: Following IR, hepatic SK2 mRNA and sphingosine-1-phosphate (S1P) levels increased ~25- and 3-fold, respectively. SK2 inhibition blunted S1P production and liver injury by 54-91%, and increased mouse survival from 28% to 100%. At 2 h after reperfusion, mitochondrial depolarization was observed in 74% of viable hepatocytes, and mitochondrial voids excluding calcein disappeared, indicating MPT onset in vivo. SK2 inhibition decreased mitochondrial depolarization and prevented MPT onset. Inducible nitric oxide synthase, phosphorylated NFκB-p65, TNFα mRNA, and neutrophil infiltration, all increased markedly after hepatic IR, and these increases were blunted by SK2 inhibition. In cultured hepatocytes, anoxia/re-oxygenation resulted in increases of SK2 mRNA, S1P levels, and cell death. SK2 siRNA and ABC294640 each substantially decreased S1P production and cell death in cultured hepatocytes.

Conclusions: SK2 plays an important role in mitochondrial dysfunction, inflammation responses, hepatocyte death, and survival after hepatic IR and represents a new target for the treatment of IR injury.

Figures
Products
  • Cat. No.
    Product Name
    Description
    Target
    Research Area
  • HY-16015
    99.68%, SphK Inhibitor